STLNWStarling Oncology, Inc.同业对比
Starling Oncology, Inc. 与SIC 8011 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STLNW本股 | $7M#11 | — | — | 0.0x#1 | 27.8%#3 | -6.3%#6 | -7.2%#7 | — | -65.7%#6 | — | -45.8%#1 | — |
| LFMDP | $1.1B#2 | — | 140.9x#6 | 5.8x#9 | 25.3%#7 | -145.9%#11 | -4.0%#5 | -141.2%#5 | — | — | — | 0.3%#2 |
| DFPH | $1.1B#3 | — | — | 2.2x#6 | 27.8%#3 | -6.3%#6 | -7.2%#7 | — | -65.7%#6 | — | — | — |
| STLN | $617M#5 | — | — | 1.2x#5 | 27.8%#3 | -6.3%#6 | -7.2%#7 | — | -65.7%#6 | — | — | — |
| SBC | $427M#6 | 8.6x#2 | 1.6x#2 | 2.5x#7 | -15.5%#9 | 9.4%#3 | 38.9%#1 | 19.3%#2 | 35.7%#2 | 3#3 | — | — |
| AIRS | $177M#7 | — | 1.7x#3 | 1.2x#4 | -15.8%#11 | -45.5%#9 | -7.6%#10 | -11.1%#4 | -8.9%#4 | — | — | — |
| LFMD | $150M#8 | — | 18.9x#4 | 0.8x#3 | 25.3%#7 | -145.9%#11 | -4.0%#5 | -141.2%#5 | — | — | — | 2.1%#1 |
| SBCWW | $30M#10 | 0.6x#1 | 0.1x#1 | 0.2x#2 | -15.5%#9 | 9.4%#3 | 38.9%#1 | 19.3%#2 | 35.7%#2 | 3#3 | — | — |
| BMGL | $89M#9 | — | — | 10.0x#11 | — | — | — | — | — | — | — | — |
| CCM | $642M#4 | — | — | 9.9x#10 | 26.6%#6 | 68.6%#1 | -57.6%#11 | — | -25.0%#5 | 6#1 | — | — |
| CDIX | — | — | — | — | 39.5%#2 | -66.7%#10 | 9.5%#3 | -313.8%#7 | 82.4%#1 | 5#2 | — | — |
| HIMS | $6.6B#1 | — | 20.3x#5 | 2.8x#8 | 59.0%#1 | 1.8%#5 | 4.5%#4 | 39.6%#1 | — | — | — | — |
| HLYK | — | — | — | — | -31.3%#12 | 46.5%#2 | -102.3%#12 | — | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-02。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议